Welcome to the official website of the Ethypharm Group. This website is regulated by the Code of Best Practices of the International Federation of Pharmaceutical Manufacturers. Some information on this site may not be in conformity with French regulations on advertising. By continuing your navigation, you accept this website's use of cookies.

News & Press releases

Check here for our latest news, press releases, and publications.


Ruud Helwig is appointed Managing Director of Ethypharm GmbH

We are pleased to announce the appointment of Ruud Helwig to the position of Managing Director of our German subsidiary – Ethypharm GmbH, effective from March 1 2018.

Ruud is an agile and entrepreneurial person with a multicultural background as he has lived and worked in many countries. Of Dutch nationality, Ruud lives today in Austria and holds a Master of Business Administration, a Master of Law and Economics and a Law Practice program of IMADEC University in Vienna.

With over 34 years of experience in the pharmaceutical industry Ruud Helwig has been involved in the commercial growth and development of international companies with markets all over the world. Among these are renowned companies such as Eli Lilly, Aspen and SkyePharma.

His broad international business development experience and strong knowledge of the pharma industry in Europe, are key to build and grow our German Subsidiary.

As Managing Director of Ethypharm Germany, his main tasks include the development and creation of new growth projects aligned to the Group’s strategy.  Among his responsibilities are the developing of promotional programs for our medicines, preparing specific portfolio product launches and initiating In-Licensing activities.

Ruud will be based close to Berlin, where our German subsidiary was founded back in 2015 with first sales in March 2016.

Integration of Partnered and International Sales Groups – Eric Vick is appointed Vice President of Global Channel Sales

The successful integration of Ethypharm and Martindale since the merger in February 2017 has allowed us to form a company with greater global reach than ever before.  We have begun the process of cross selling Ethypharm and Martindale products and examples such as the launch of Noyada in France or Esomeprazole growth in the UK have shown us to be better together.  The International businesses have also been able to find new opportunities to take products such as Fencino and Zomorph into markets in MENA.

Ethypharm Group has assessed options for managing the business derived via our non-direct sales channels, and has decided to establish a new group, Global Channel Sales.

Global Channel Sales will encompass our growing list of distributors, license partners, and NGOs, generating sales across 80+ countries.  Our goal is to develop an organisation that can leverage our local expertise, proactively manage our established business relationships, and identify new growth opportunities.  With a target budget in excess of €140mn in 2018, the performance of the new group will be a core component of the overall Ethypharm Group success.

We are pleased to confirm that Eric Vick has been appointed as Vice President of Global Channel Sales. Eric brings to this role a strong pedigree in global sales management, a customer-focused business approach, and a drive to achieve the full potential of the business.

We wish Eric every success in this challenging new role.


Michael Harris becomes Ethypharm’s Chief Operating Officer

Ethypharm, a European specialty pharmaceutical company, announces the appointment of Michael Harris as Chief Operating Officer of the Ethypharm Group.

Learn more

Ethypharm and Camurus sign agreement for distribution of episil® in France

Camurus AB and Ethypharm announced today that they have entered into an agreement under which Ethypharm has obtained exclusive distribution rights for episil® oral liquid in France. Based on a patented technology, episil® is an innovative treatment for the management and relief of oral mucositis pain, a common treatment-limiting side effect of cancer therapies.

Learn more

By clicking on this link, you agree to leave our website.
Are you sure?
NO     YES